News Release

Antibody response of 3-dose COVID-19 vaccination schedule in immunocompromised patients with hematologic cancers

JAMA Oncology

Peer-Reviewed Publication

JAMA Network

About The Study: In this study that included 584 immunocompromised patients with hematologic cancers, a third Moderna COVID-19 vaccination was associated with significantly improved SARS-CoV-2 antibody concentrations comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.

Authors: Mette D. Hazenberg, M.D., Ph.D., of the University of Amsterdam, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.